Kilpatrick Townsend’s Silicon Valley-based start-up team advised the founders of Editas Medicine in the biotech start-up’s $43 million Series A Financing. In a trend setting transaction, venture firms Polaris Partners, Third Rock Ventures, Flagship Ventures and the Partners Innovation Fund invited five of the most prominent research scientists in the field of genomics from MIT, Harvard, the Howard Hughes Medical Institute and the University of California in Berkeley to form a company which they would fund. The money invested will fund the collaborative research and development by this world-class team of scientists as they seek to revolutionize the treatment of genetic disorders by developing a simple, precise and inexpensive method of ‘editing out’ abnormalities in genes in human cells.

Experience Center

Match our Experience to Your Needs

View All Case Studies

Experience Highlights

Convinced DOJ not to take action in a theft of trade secret investigation
In less than three months, we convinced the Department of Justice not to take any action against a client employee for allegedly stealing trade more
DIAC arbitration for an international engineering firm
Lead counsel to an international engineering firm providing engineering, design, planning, and construction services around the world, in a DIAC more
Public-private partnership for private development of a large U.S. public school system
Represented one of the 25 largest U.S. public school systems in a public-private partnership for the private development of public schools. more
Transactions for brokerage firms
Represented one of the leading U.S.-based brokerage firms in commercial loan transactions for its brokerage customers; loans secured by real and more